Sofgen Pharma SAPROCF
13F holders, Q2 2024 (June 30)7holders −2
1new positions
3sold out
$2.53avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Sofgen Pharma SA (PROCF) in their 13F filings, down 2 from Q1 2024. 1 opened new positions and 3 sold out. The largest holders were Exome Asset Management LLC ($321K), Geode Capital Management, LLC ($73K) and State Street Corp. ($31K).
- Company
- Sofgen Pharma SA
- Filed as
- PROCAPS GROUP SA (Q2 2024)
- CUSIP
- L7756P102
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $321K |
| Exits | 3 | $112K |
All 13F filers, Q1 2024 → Q2 2024: 127,050 shares bought and 37,842 shares sold, net +89,208 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Exome Asset Management LLC | 0.29% | New | 126,901 | $321K |
| Geode Capital Management, LLC | 0.00% | No change | 28,938 | $73K |
| State Street Corp. | 0.00% | Add +0.2% | 12,383 | $31K |
| Activest Wealth Management | 0.01% | No change | 10,000 | $25K |
| Royal Bank of Canada | 0.00% | Add +35.6% | 491 | $1K |
| Pineridge Advisors LLC | 0.00% | No change | 250 | $628 |
| Morgan Stanley | 0.00% | No change | 100 | $251 |
"% of holder's portfolio" is PROCF's weight in each manager's 13F, not the share of Sofgen Pharma SA the manager owns.